Spots Global Cancer Trial Database for Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation

Official Title: Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation

Study ID: NCT01339572

Conditions

Non-Hodgkin's Lymphoma

Multiple Myeloma

Interventions

Plerixafor

Filgrastim

Study Description

Brief Summary: This protocol will investigate the effectiveness of plerixafor in the up-front setting in avoiding a second round of mobilization and whether this translates into a clinical and economic benefit.

Detailed Description: Peripheral blood stem cells are now considered the standard source of stem cells for autologous stem cell transplants. Unfortunately, there is still a 20-30% chance that inadequate numbers of stem cells will be collected, resulting in prolonged recovery of cell counts after transplantation and increased transfusion dependence. There is also a significant economic burden associated with remobilization and a risk that delays in collecting sufficient numbers of stem cells can result in an increased chance of disease recurrence prior to transplantation.